GENMAB A/S/S (GMXAY) Stock Price, News & Analysis

Company Overview

Genmab A/S is a Denmark-based biotechnology company focused on discovering, developing, and commercializing antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including its DuoBody and HexaBody platforms, to develop therapies designed to engage the immune system and target disease-related mechanisms.

Genmab’s marketed and partnered products include DARZALEX (daratumumab) for certain blood cancers, EPKINLY (epcoritamab) for certain types of B-cell lymphoma, and Tivdak (tisotumab vedotin) for cervical cancer. The company has also contributed to the development of other antibody medicines, including ofatumumab, which is marketed by Novartis as Kesimpta for multiple sclerosis. Genmab typically commercializes products through strategic collaborations with larger pharmaceutical companies.

Founded in 1999 and headquartered in Copenhagen, Genmab serves international markets through its global development, research, and commercial partnerships. The company’s operations and collaborations span North America, Europe, and other major pharmaceutical markets. Dr. Jan van de Winkel has served as Genmab’s president and chief executive officer and has been a central figure in the company’s research and corporate development.

Key Stats

• Today's Range: $51.22 to $54.15
• 50-Day Range: $32.47 to $57.06
• 52-Week Range: $12.10 to $19.00
• Volume: 7.83 million shs
• Average Volume: 48,553 shs
• Market Capitalization: N/A
• P/E Ratio: 20.59
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:GMXAY
• CIK: N/A
• Web: www.genmab.com
• Phone: 45 70 20 27 28
• Fax: N/A
• Employees: 1,660
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 20.59
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A